NCI-2022-00860

Phase 1/2 Study of the Safety, Pharmacokinetics, and Preliminary Clinical Activity of BT7480 in Patients With Nectin-4 Associated Advanced Malignancies

In this Phase 1/2 study, researchers are investigating BT7480, a potential treatment, in patients who have advanced malignancies associated with Nectin-4. They aim to understand how safe the treatment is, how it moves through the body, and its initial effectiveness in treating these types of cancers.

Phase 1/2 study: A study that assesses the safety, effectiveness, and how well the treatment works

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT05163041

Clinical Trial Site: Columbia

To see all available clinical trials click here.